A clue to a deal, page-16

Boehringer Ingelheim this week announced successful Phase 1 results for its drug, BI 771716 in the treatment of geographic atrophy.

The 20 patient study tested both single and multiple intravitreal doses (2 doses with a 4 week interval between). The primary endpoint was the incidence of ocular dose-limiting events from treatment until day 8. The primary safety endpoint was met for both the single and multiple doses.

Boehringer Ingelheim licensed the antibody fragment-based therapeutic from Swiss company, CDR-Life, in mid-2020. When delivered via intravitreal injection, high affinity antibody fragment therapies have the potential to penetrate through the retinal layers to reach the RPE cells where degeneration is known to occur. The drug aims to prevent further loss of sight by decreasing the cellular stresses caused by AMD.

Under the terms of the 2020 licensing and collaboration agreement, Boehringer Ingelheim was to receive an exclusive, worldwide license to develop certain compounds for the treatment of geographic atrophy based on CDR-Life’s technology against a specific target. Boehringer was to be responsible for global development and commercialization.

CDR-Life was to be eligible to receive up to CHF 474.5 million (A$ 840m) in upfront and success-based milestone payments, as well as research funding and royalties on sales.

It is now planned to commence Phase 2 early next year, marking the achievement of the fourth milestone payment under the collaboration and licensing agreement.

https://www.clinicaltrialsarena.com/news/boehringer-geographic-atrophy-trial/

https://www.ophthalmologytimes.com/...ic-atrophy-following-positive-phase-i-results

https://www.boehringer-ingelheim.co...tibody-fragment-based-therapeutics-geographic

https://clinicaltrials.gov/study/NCT06006585?intr=BI 771716&rank=1